10 facts about metformin Review article
Article Sidebar
Published:
Dec 31, 2018
Keywords:
diabetes, metformin, treatment
Main Article Content
Abstract
Metformin, apart from its antidiabetic effects, reducing insulin resistance, has a number of additional effects, such as reducing the risk of cardiovascular complications, reducing body weight, a favourable lipid profile and reducing the development of diabetes in people with pre-diabetic condition. The recommendations of the Polish Diabetes Association recommend metformin as the first choice drug in the treatment of type 2 diabetes.
Article Details
How to Cite
Duda-Król, W. B. (2018). 10 facts about metformin. Medycyna Faktow (J EBM), 11(4(41), 344-347. https://doi.org/10.24292/01.MF.0418.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. International Diabetes Federation, 2017 [Online].
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2018. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabet. Prakt. 2018; 4(1): 24-26.
3. Bailey C.J., Day C.: Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12(8): 553-564.
4. Bailay C.J., Campbell I., Chan J. et al.: Metformina – złoty standard. Via Medica, Gdańsk 2008.
5. Duda-Król W.B., Mamcarz A.: Renesans metforminy – 33 pytania i odpowiedzi Medical Education, Warszawa 2008.
6. Holman R.R., Paul S.K., Bethel M.A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-1589.
7. Wright A.D., Cull C.A., Macleod K.M. et al.: Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complications 2006; 20: 395-401.
8. UK Prospective Diabetes Study Group (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. UK Prospective Diabetes Study Group (UKPDS): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
10. Malin S.K., Kashyap S.R.: Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 2014; 21: 323-329.
11. Abbasi F., Carantoni M., Chen Y.D. et al.: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998; 21: 1301-1305.
12. Palumbo P.J.: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications 1998; 12: 110-119.
13. Holman R.R., Paul S.K., Bethel M.A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-1589.
14. Griffin S.J., Leaver J.K., Irving G.J.: Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017; 60(9): 1620-1629.
15. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393-403.
16. Diabetes Prevention Program Research Group, Knowler W.C., Fowler S.E., Hamman R.F. et al.: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
17. Jasik M.: Zastosowanie metforminy u kobiet z zespołem policystycznych jajników. Diabetologia po Dyplomie 2016; 4: 22-25.
18. Metformina. Baza leków, Medycyna praktyczna [online].
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2018. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabet. Prakt. 2018; 4(1): 24-26.
3. Bailey C.J., Day C.: Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12(8): 553-564.
4. Bailay C.J., Campbell I., Chan J. et al.: Metformina – złoty standard. Via Medica, Gdańsk 2008.
5. Duda-Król W.B., Mamcarz A.: Renesans metforminy – 33 pytania i odpowiedzi Medical Education, Warszawa 2008.
6. Holman R.R., Paul S.K., Bethel M.A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-1589.
7. Wright A.D., Cull C.A., Macleod K.M. et al.: Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complications 2006; 20: 395-401.
8. UK Prospective Diabetes Study Group (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. UK Prospective Diabetes Study Group (UKPDS): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
10. Malin S.K., Kashyap S.R.: Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 2014; 21: 323-329.
11. Abbasi F., Carantoni M., Chen Y.D. et al.: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998; 21: 1301-1305.
12. Palumbo P.J.: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications 1998; 12: 110-119.
13. Holman R.R., Paul S.K., Bethel M.A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-1589.
14. Griffin S.J., Leaver J.K., Irving G.J.: Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017; 60(9): 1620-1629.
15. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393-403.
16. Diabetes Prevention Program Research Group, Knowler W.C., Fowler S.E., Hamman R.F. et al.: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
17. Jasik M.: Zastosowanie metforminy u kobiet z zespołem policystycznych jajników. Diabetologia po Dyplomie 2016; 4: 22-25.
18. Metformina. Baza leków, Medycyna praktyczna [online].